Placeholder

Ferric Carboxymaltose

CAS No:
9007-72-1 Categories: , ,
  • # LGM Pharma is a Ferric Carboxymaltose CAS# 9007-72-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ferric Carboxymaltose
  • CAS #: 9007-72-1
  • Mode of Action:

    Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that release iron.

  • Pharmacodynamics:

    When measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red cell uptake ranged from 61% to 84%.

  • Toxicity:

    The most common adverse reactions (>2%) are nausea, hypertension, flushing, hypophosphatemia, and dizziness.

  • IUPAC: Iron(3+) hydroxide oxide poly-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-gluconate hydrate
  • DrugBank: DB08917
  • Molecular Mass: 788.4316
  • Synonyms: Ferinject Ferric carboxymaltose Injectafer Iron Dextri-Maltose Polynuclear iron (III)-hydroxide 4(R)-(poly-(1->4)-O-alpha-D-glucopyranosyl)-oxy- 2(R),3(S),5(R), 6-tetrahydroxy-hexanoate UNII-6897GXD6OE VIT 45 VIT-45
  • AHFS Code: 20:04.0
  • General Reference:

    FDA label

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service